

Evaluating Approaches for Constructing Polygenic Risk Scores for Prostate Cancer in Men of African and European Ancestry

Burcu F. Darst^{1,2*}, Jiayi Shen^{1*}, Ravi K. Madduri³, Alexis A. Rodriguez³, Yukai Xiao³, Xin Sheng¹, Edward J. Saunders⁴, Tokhir Dadaev⁴, Mark N. Brook⁴, Thomas J. Hoffmann⁵, Kenneth Muir⁶, Peggy Wan¹, Loic Le Marchand⁷, Lynne Wilkens⁷, Ying Wang⁸, Johanna Schleutker⁹, Robert J. MacInnis^{10,11}, Cezary Cybulski¹², David E. Neal^{13,14,15}, Børge G. Nordestgaard^{16,17}, Sune F. Nielsen^{16,17}, Jyotsna Batra^{18,19}, Judith A. Clements^{18,19}, Australian Prostate Cancer BioResource^{19,20}, Henrik Grönberg²¹, Nora Pashayan^{22,23}, Ruth C. Travis²⁴, Jong Y. Park²⁵, Demetrius Albanes²⁶, Stephanie Weinstein²⁶, Lorelei A. Mucci²⁷, David J. Hunter²⁸, Kathryn L. Penney²⁹, Catherine M. Tangen³⁰, Robert J. Hamilton^{31,32}, Marie-Élise Parent^{33,34}, Janet L. Stanford^{2,35}, Stella Koutros²⁶, Alicja Wolk^{36,37}, Karina D. Sørensen^{38,39}, William J. Blot^{40,41}, Edward D. Yeboah^{42,43}, James E. Mensah^{42,43}, Yong-Jie Lu⁴⁴, Daniel J. Schaid⁴⁵, Stephen N. Thibodeau⁴⁶, Catharine M. West⁴⁷, Christiane Maier⁴⁸, Adam S. Kibel⁴⁹, Géraldine Cancel-Tassin^{50,51}, Florence Menegaux⁵², Esther M. John^{53,54,55}, Eli Marie Grindedal⁵⁶, Kay-Tee Khaw⁵⁷, Sue A. Ingles⁵⁸, Ana Vega^{59,60,61}, Barry S. Rosenstein^{62,63}, Manuel R. Teixeira^{64,65}, NC-LA PCaP Investigators^{66,67,68}, Manolis Kogevinas^{69,70,71,72}, Lisa Cannon-Albright^{73,74}, Chad Huff⁷⁵, Luc Multigner⁷⁶, Radka Kaneva⁷⁷, Robin J. Leach⁷⁸, Hermann Brenner^{79,80,81}, Ann W. Hsing⁸², Rick A. Kittles⁸³, Adam B. Murphy⁸⁴, Christopher J. Logothetis⁸⁵, Susan L. Neuhausen⁸⁶, William B. Isaacs⁸⁷, Barbara Nemesure⁸⁸, Anselm J. Hennis^{88,89}, John Carpten⁹⁰, Hardev Pandha⁹¹, Kim De Ruyck⁹², Jianfeng Xu⁹³, Azad Razack⁹⁴, Soo-Hwang Teo⁹⁵, Canary PASS Investigators^{2,96}, Lisa

F. Newcomb^{2,96}, Jay H. Fowke⁹⁷, Christine Neslund-Dudas⁹⁸, Benjamin A. Rybicki⁹⁸, Marija Gamulin⁹⁹, Nawaid Usmani^{100,101}, Frank Claessens¹⁰², Manuela Gago-Dominguez^{103,104}, Jose Esteban Castela¹⁰⁵, Paul A. Townsend^{106,107}, Dana C. Crawford¹⁰⁸, Gyorgy Petrovics¹⁰⁹, Graham Casey¹¹⁰, Monique J. Roobol¹¹¹, Jennifer F. Hu¹¹², Sonja I. Berndt²⁶, Stephen K. Van Den Eeden^{113,114}, Douglas F. Easton²³, Stephen J. Chanock²⁶, Michael B. Cook²⁶, Fredrik Wiklund²¹, John S. Witte¹¹⁵, Rosalind A. Eeles^{116,117}, Zsafia Kote-Jarai¹¹⁶, Stephen Watya¹¹⁸, John M. Gaziano^{119,120,121}, Amy C. Justice^{122,123}, David V. Conti¹, Christopher A. Haiman¹

¹Center for Genetic Epidemiology, Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

²Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA

³Argonne National Laboratory, Lemont, IL, USA

⁴The Institute of Cancer Research, London, UK

⁵Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

⁶Division of Population Health, Health Services Research and Primary Care, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

⁷Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA

⁸Department of Population Science, American Cancer Society, Atlanta, GA, USA

⁹Institute of Biomedicine, University of Turku, Finland

¹⁰Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia

¹¹Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Victoria, Australia

¹²International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland

¹³Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK

¹⁴University of Cambridge, Department of Oncology, Addenbrooke's Hospital, Cambridge, UK

¹⁵Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Cambridge UK

¹⁶Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

¹⁷Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Copenhagen, Denmark

¹⁸Australian Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation and School of Biomedical Sciences, Queensland University of Technology, Brisbane, Australia

¹⁹Translational Research Institute, Brisbane, Queensland, Australia

²⁰Australian Prostate Cancer Research Centre-Qld, Queensland University of Technology, Brisbane; Prostate Cancer Research Program, Monash University, Melbourne; Dame Roma Mitchell Cancer Centre, University of Adelaide, Adelaide; Chris O'Brien Lifehouse and The Kinghorn Cancer Centre, Sydney, Australia

²¹Department of Medical Epidemiology and Biostatistics, Karolinska Institute,

Stockholm, Sweden

²²University College London, Department of Applied Health Research, London, UK

²³Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK

²⁴Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK

²⁵Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA

²⁶Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, MD, USA

²⁷Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA, USA

²⁸Nuffield Department of Population Health, University of Oxford, Oxford, UK

²⁹Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA

³⁰SWOG Statistical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA

³¹Dept. of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Canada

³²Dept. of Surgery (Urology), University of Toronto, Canada

³³Epidemiology and Biostatistics Unit, Centre Armand-Frappier Santé Biotechnologie, Institut national de la recherche scientifique, Laval, QC, Canada

³⁴Department of Social and Preventive Medicine, School of Public Health, University of Montreal, Montreal, QC, Canada

³⁵Department of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA

³⁶Division of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

³⁷Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

³⁸Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark

³⁹Department of Clinical Medicine, Aarhus University, Aarhus N, Denmark

⁴⁰Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

⁴¹International Epidemiology Institute, Rockville, MD, USA

⁴²University of Ghana Medical School, Accra, Ghana

⁴³Korle Bu Teaching Hospital, Accra, Ghana

⁴⁴Centre for Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK

⁴⁵Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

⁴⁶Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

⁴⁷Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Radiotherapy Related Research, The Christie Hospital NHS Foundation Trust, Manchester, UK

⁴⁸Humangenetik Tuebingen, Tuebingen, Germany

⁴⁹Division of Urologic Surgery, Brigham and Womens Hospital, Boston, MA, USA

⁵⁰CeRePP, Tenon Hospital, Paris, France

⁵¹Sorbonne Universite, GRC 5 Predictive Onco-urology, Tenon Hospital, Paris, France

⁵²"Exposome and Heredity", CESP (UMR 1018), Faculté de Médecine, Université Paris-Saclay, Inserm, Gustave Roussy, Villejuif, France

⁵³Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA

⁵⁴Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

⁵⁵Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA

⁵⁶Department of Medical Genetics, Oslo University Hospital, Oslo, Norway

⁵⁷Clinical Gerontology Unit, University of Cambridge, Cambridge, UK

⁵⁸Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁵⁹Fundación Pública Galega Medicina Xenómica, Santiago De Compostela, Spain

⁶⁰Instituto de Investigación Sanitaria de Santiago de Compostela, Santiago De Compostela, Spain

⁶¹Centro de Investigación en Red de Enfermedades Raras (CIBERER), Spain

⁶²Department of Radiation Oncology and Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁶³Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA

⁶⁴Department of Genetics, Portuguese Oncology Institute of Porto (IPO-Porto), Porto, Portugal

⁶⁵Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal

⁶⁶Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

⁶⁷Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill,

NC, USA

⁶⁸Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA

⁶⁹ISGlobal, Barcelona, Spain

⁷⁰IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain

⁷¹Universitat Pompeu Fabra (UPF), Barcelona, Spain

⁷²CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain

⁷³Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

⁷⁴George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA

⁷⁵Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

⁷⁶Univ Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail), Rennes, France

⁷⁷Molecular Medicine Center, Department of Medical Chemistry and Biochemistry, Medical University of Sofia, Sofia, Bulgaria

⁷⁸Department of Urology, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio Texas, USA

⁷⁹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany

⁸⁰German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany

⁸¹Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany

⁸²Department of Medicine and Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA

⁸³Division of Health Equities, Department of Population Sciences, City of Hope, Duarte, CA, USA

⁸⁴Department of Urology, Northwestern University, Chicago, IL, USA

⁸⁵The University of Texas M. D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, Houston, TX, USA

⁸⁶Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA, USA

⁸⁷James Buchanan Brady Urological Institute, Johns Hopkins Hospital and Medical Institution, Baltimore, MD, USA

⁸⁸Department of Family, Population and Preventive Medicine, Stony Brook University, Stony Brook, NY, USA

⁸⁹Chronic Disease Research Centre and Faculty of Medical Sciences, University of the West Indies, Bridgetown, Barbados

⁹⁰Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

⁹¹Faculty of Health and Medical Sciences, The University of Surrey, Guildford, Surrey, UK

⁹²Ghent University, Faculty of Medicine and Health Sciences, Basic Medical Sciences, Gent, Belgium

⁹³Program for Personalized Cancer Care and Department of Surgery, NorthShore University HealthSystem, Evanston, IL, USA

⁹⁴Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia

⁹⁵Cancer Research Malaysia (CRM), Outpatient Centre, Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia

⁹⁶Department of Urology, University of Washington, Seattle, WA, USA

⁹⁷Division of Epidemiology, Department of Preventive Medicine, The University of Tennessee Health Science Center, TN, USA

⁹⁸Department of Public Health Sciences, Henry Ford Hospital, Detroit, MI, USA

⁹⁹Department of Oncology, University Hospital Centre Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia

¹⁰⁰Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada

¹⁰¹Division of Radiation Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada

¹⁰²Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium

¹⁰³Genomic Medicine Group, Galician Foundation of Genomic Medicine, Instituto de Investigacion Sanitaria de Santiago de Compostela (IDIS), Complejo Hospitalario Universitario de Santiago, Servicio Galego de Saúde, SERGAS, Santiago de Compostela, Spain

¹⁰⁴University of California San Diego, Moores Cancer Center, La Jolla, CA, USA

¹⁰⁵Genetic Oncology Unit, CHUVI Hospital, Complejo Hospitalario Universitario de

Vigo, Instituto de Investigación Biomédica Galicia Sur (IISGS), Vigo (Pontevedra),
Spain

¹⁰⁶Division of Cancer Sciences, Manchester Cancer Research Centre, Faculty of
Biology, Medicine and Health, Manchester Academic Health Science Centre, NIHR
Manchester Biomedical Research Centre, Health Innovation Manchester, University of
Manchester, UK

¹⁰⁷The University of Surrey, Guildford, Surrey, UK

¹⁰⁸Case Western Reserve University, Department of Population and Quantitative Health
Sciences, Cleveland Institute for Computational Biology, Cleveland, OH, USA

¹⁰⁹Center for Prostate Disease Research, Uniformed Services University, Bethesda,
MD, USA

¹¹⁰Center for Public Health Genomics, Department of Public Health Sciences, University
of Virginia, Charlottesville, VA, USA

¹¹¹109 Department of Urology, Erasmus University Medical Center, Cancer Institute,
Rotterdam, The Netherlands

¹¹²The University of Miami School of Medicine, Sylvester Comprehensive Cancer
Center, Miami, FL, USA

¹¹³Division of Research, Kaiser Permanente, Northern California, Oakland, CA, USA

¹¹⁴Department of Urology, University of California San Francisco, San Francisco, CA,
USA

¹¹⁵Department of Epidemiology and Population Health, Department of Biomedical Data
Science, Stanford Cancer Institute, Stanford, CA, USA

¹¹⁶The Institute of Cancer Research, Sutton, London, UK

¹¹⁷Royal Marsden NHS Foundation Trust, London, UK

¹¹⁸School of Public Health, Makerere University College of Health Sciences, Kampala
Uganda

¹¹⁹VA Boston Healthcare System, Boston, MA, USA

¹²⁰Department of Medicine, Harvard Medical School, Boston, MA, USA

¹²¹Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

¹²²VA Connecticut Healthcare System, West Haven, CT, USA

¹²³Yale School of Medicine, New Haven, CT, USA

‡ Co-first authorship

*Corresponding Author

Burcu F. Darst

1100 Fairview Ave N

Seattle, WA 98109

1-206-667-1036

bdarst@fredhutch.org

Abstract

Genome-wide polygenic risk scores (GW-PRS) have been reported to have better predictive ability than PRS based on genome-wide significance thresholds across numerous traits. We compared the predictive ability of several GW-PRS approaches to a recently developed PRS of 269 established prostate cancer risk variants from multi-ancestry GWAS and fine-mapping studies (PRS₂₆₉). GW-PRS models were trained using a large and diverse prostate cancer GWAS of 107,247 cases and 127,006 controls used to develop the multi-ancestry PRS₂₆₉. Resulting models were independently tested in 1,586 cases and 1,047 controls of African ancestry from the California/Uganda Study and 8,046 cases and 191,825 controls of European ancestry from the UK Biobank and further validated in 13,643 cases and 210,214 controls of European ancestry and 6,353 cases and 53,362 controls of African ancestry from the Million Veteran Program. In the testing data, the best performing GW-PRS approach had AUCs of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men and corresponding prostate cancer OR of 1.83 (95% CI=1.67-2.00) and 2.19 (95% CI=2.14-2.25), respectively, for each SD unit increase in the GW-PRS. However, compared to the GW-PRS, in African and European ancestry men, the PRS₂₆₉ had larger or similar AUCs (AUC=0.679, 95% CI=0.659-0.700 and AUC=0.845, 95% CI=0.841-0.849, respectively) and comparable prostate cancer OR (OR=2.05, 95% CI=1.87-2.26 and OR=2.21, 95% CI=2.16-2.26, respectively). Findings were similar in the validation data. This investigation suggests that current GW-PRS approaches may not improve the ability to predict prostate cancer risk compared to the multi-ancestry PRS₂₆₉ constructed with fine-mapping.

Main Text

Prostate cancer is the second leading cause of cancer deaths among men in the US, with incidence rates being highest in men of African ancestry^{1,2}. Earlier identification of men with increased risk of prostate cancer across diverse populations has the potential to reduce the stark health disparities of this disease. We recently performed a large and diverse genome-wide association (GWAS) of prostate cancer in men from African, European, East Asian, and Hispanic populations³. By performing ancestry-specific and multi-ancestry GWAS and fine-mapping analyses, this investigation revealed 269 GWAS-defined prostate cancer risk variants used to develop a multi-ancestry polygenic risk score (PRS₂₆₉). The PRS₂₆₉ was highly predictive of prostate cancer risk across populations³ and has since been validated in additional independent multi-ancestry studies⁴. However, genome-wide PRS (GW-PRS) approaches, which include variants across the genome that do not reach genome-wide statistical significance thresholds, have been reported to have better predictive performance than standard pruning and thresholding PRS of known variants across numerous complex traits, including schizophrenia, coronary artery disease, atrial fibrillation, type 2 diabetes, inflammatory bowel disease, breast cancer, and colorectal cancer⁵⁻⁹.

In this investigation, we compared the predictive ability of GW-PRS for prostate cancer to the multi-ancestry PRS₂₆₉ of established prostate cancer risk variants. GW-PRS models were trained using summary statistics from the studies used to construct the multi-ancestry PRS₂₆₉, which included 107,247 cases and 127,006 controls from European (85,554 cases and 91,972 controls), African (10,368 cases and 10,986 controls), East Asian (8,611 cases and 18,809 controls), and Hispanic (2,714 cases and

5,239 controls) populations³. Three recent GW-PRS approaches were evaluated: LDpred²¹⁰, PRS-CSx¹¹, and EB-PRS¹², using the 1.1 million HapMap3 panel variants¹³ recommended by these approaches, which included 44 of the 269 variants, with all other autosomal prostate cancer risk variants being within 800 kb and correlated with a median $r=0.99$ (ranging from 0.31-1.00 in any given population) of at least one of the 1.1 million HapMap3 variants (**Supplemental Methods** and **Tables S1-S2**). For comparison, each model was trained using previously estimated multi-ancestry weights and population-specific weights from the GWAS summary statistics³. GW-PRS models were tested in African ancestry men from the California/Uganda Study (CA/UG Study; 1,586 cases and 1,047 controls) and European ancestry men from the UK Biobank (8,046 cases and 191,825 controls; **Supplemental Methods**). Additional validation was performed in 6,353 cases and 53,362 controls of African ancestry and 13,643 cases and 210,214 controls of European ancestry from the Million Veteran Program¹⁴ (MVP; **Supplemental Methods**).

In the CA/UG and UK Biobank testing datasets, the best performing GW-PRS approach was PRS-CSx with multi-ancestry weights, with an area under the curve (AUC) of 0.656 (95% CI=0.635-0.677) in African and 0.844 (95% CI=0.840-0.848) in European ancestry men (**Supplemental Methods, Figure 1, and Table S3**). Each SD unit increase in PRS was associated with 1.83-fold higher odds of prostate cancer (95% CI=1.67-2.00) in men of African ancestry and 2.19-fold higher odds of prostate cancer (95% CI=2.14-2.25) in men of European ancestry (**Supplemental Methods, Figure 1, and Table S4**). However, compared to PRS-CSx, the PRS₂₆₉ had higher or nearly identical AUCs in both African (0.679, 95% CI=0.659-0.700) and European (0.845, 95%

CI=0.841-0.849) ancestry men, and the PRS₂₆₉ was associated with 2.05-fold higher odds (95% CI=1.87-2.26) and 2.21-fold higher odds (95% CI=2.16-2.26) of prostate cancer in African and European ancestry men, respectively (**Figure 1, Table S3, and Table S4**). Findings were consistent when investigating extreme PRS distributions, with similar prostate cancer OR observed for the PRS₂₆₉ and the best performing GW-PRS (PRS-CSx) when comparing African and European ancestry men in the highest PRS decile (90-100%) to those in the average 40-60% PRS category (**Supplemental Methods, Figure S1, and Table S5**).

Similarly, in the validation MVP study, the best performing GW-PRS approach was PRS-CSx with multi-ancestry weights; however, the PRS₂₆₉ performed either better or similarly with regards to AUC (AUC=0.656 [95% CI=0.649-0.663] versus AUC=0.624 [95% CI=0.617-0.632] in African ancestry men; AUC=0.694 [95% CI=0.690-0.699] versus AUC=0.692 [95% CI=0.687-0.696] in European ancestry men; **Figure 2 and Table S3**). Likewise, the PRS₂₆₉ was associated with prostate cancer OR that were comparable or larger than OR estimated with PRS-CSx (OR=1.77, 95% CI=1.72-1.82 versus OR=1.59, 95% CI=1.54-1.63 in African ancestry men; OR=1.99, 95% CI=1.95-2.02 versus OR=1.97, 95% CI=1.93-2.01 in European ancestry men; **Figure 2 and Table S4**). OR calculated for African and European men in the top PRS decile were also comparable across the PRS₂₆₉ and PRS-CSx (**Figure S2 and Table S5**). In the testing and validation datasets, model performance was similar for both PRS₂₆₉ and GW-PRS approaches when using either multi-ancestry or population-specific weights (**Figures 1-2, Figures S1-S2, and Tables S3-S5**).

Findings from this investigation suggest that current GW-PRS approaches do not outperform the multi-ancestry PRS₂₆₉ for overall prostate cancer risk prediction. For several other disease examples, GW-PRS have been shown to perform better than PRS of known variants⁵⁻⁹; however, these PRS are typically constructed from a pruning and thresholding approach within European ancestry individuals rather than a fine-mapping approach across diverse populations. As such, the performance observed for our prostate cancer PRS₂₆₉ may be due to identifying GWAS risk variants from a multi-ancestry GWAS and fine-mapping study, along with the use of the same multi-ancestry GWAS to construct the GW-PRS³. It is also possible that the unique genetic architecture of prostate cancer contributes to the high performance of the PRS₂₆₉ across populations, as prostate cancer is one of the most heritable cancers^{15,16} and has been estimated to display a greater distribution of variants with larger effect sizes than other cancers with similar GWAS sample sizes⁹.

We have previously shown that GW-PRS including variants with weaker statistical evidence of association in both European and African ancestry men (based on lenient P-value thresholds down to 1.0×10^{-5}) resulted in lower PRS performance³. Likewise, it was recently reported that a GW-PRS constructed from 1 million variants most strongly associated with prostate cancer risk led to comparable results as a GW-PRS based on HapMap3 variants¹⁷, further suggesting that GW-PRS approaches may not be improved by selecting a large number of variants weakly associated with prostate cancer risk. Last, a European-ancestry derived PRS of 110 established literature-curated prostate cancer risk variants was previously found to perform better than a GW-PRS in addition to a standard pruning and thresholding PRS¹⁸. These findings in

conjunction with the present study suggest that the current multi-ancestry and fine-mapped PRS₂₆₉ is optimal, which has important clinical implications. While genotyping a few hundred versus millions of variants to construct PRS is currently logistically easier and more cost-effective, genome-wide genotyping may be optimal in the future to enable the evaluation of PRS across many traits. However, our findings do not imply that the multi-ancestry PRS₂₆₉ has reached optimal performance; increasing the sample size of non-European ancestry men in the discovery GWAS, particularly African ancestry men, where we and others have observed that the PRS has lower performance than in other populations^{3,4}, will be important to improve genetic risk prediction of prostate cancer. The multi-ancestry PRS₂₆₉ is an effective risk stratification tool for prostate cancer, and its clinical utility in screening and early detection warrants investigation.

Acknowledgements

This work was supported by the National Cancer Institute at the National Institutes of Health grant (grant numbers U19 CA214253 to C.A.H., R01 CA257328 to C.A.H., U19 CA148537 to C.A.H., R01 CA165862 to C.A.H., and R00 CA246063 to B.F.D.), the Prostate Cancer Foundation (grants 21YOUN11 to B.F.D. and 20CHAS03 to C.A.H.), an award from the Andy Hill Cancer Research Endowment Distinguished Researchers Program (B.F.D.), a Fred Hutch/University of Washington SPORE Career Enhancement Program award (BFD), and the Million Veteran Program-MVP017. This research has been conducted using the UK Biobank Resource under application number 42195. This research is based on data from the Million Veteran Program, Office of Research and Development and the Veterans Health Administration. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.

Author Contributions

Study conception/design: BFD, DVC, CAH; Provided data: RKM, XS, EJS, TD, MNB, TJH, KM, PW, LLM, LW, YW, LS, RJM, CC, DEN, BGN, SFN, JB, JAC, APCB, HG, NP, RCT, JYP, DA, SW, LAM, DJH, KLP, CMT, RJH, MP, JLS, SK, AW, KDS, WJB, EDY, JEM, YL, SNT, CMW, CM, ASK, GC, FM, EMJ, EMG, KK, SAI, AV, BSB, MRT, NCPI, MK, LC, CH, LM, RK, RJL, HB, AWH, RAK, ABM, CJL, SLN, WBI, BN, AJH, JC, HP, KDR, JX, AR, ST, CPI, LFN, JF, CN, BAR, MG, NU, FC, MG, JEC, PAT, DCC, GP, GC, MFR, JFH, SIB, SKVDE, DFE, SJC, MBC, FW, JSW, RAE, AK, SW, JMG, ACJ, DVC, CAH; Data analysis: BFD, JS, YX, AAR; Bioinformatics support: XS, RKM;

Interpretation of data: BFD, DVC, CAH; Drafted the manuscript: BFD; Contributed to manuscript revisions: BFD, JS, XS, EJS, EMJ, DJS, NP, DVC, CAH; All authors approved of the final manuscript.

Competing Interests Statement

The authors have no conflicts of interest to disclose.

References

1. Howlander, N., Noone, A.M., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., Lewis, D.R., et al. (2020). SEER Cancer Statistics Review, 1975-2017. National Cancer Institute.
2. Kolonel, L.N., Henderson, B.E., Hankin, J.H., Nomura, A.M., Wilkens, L.R., Pike, M.C., Stram, D.O., Monroe, K.R., Earle, M.E., and Nagamine, F.S. (2000). A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. *Am J Epidemiol* 151, 346-357. [10.1093/oxfordjournals.aje.a010213](https://doi.org/10.1093/oxfordjournals.aje.a010213).
3. Conti, D.V., Darst, B.F., Moss, L.C., Saunders, E.J., Sheng, X., Chou, A., Schumacher, F.R., Olama, A.A.A., Benlloch, S., Dadaev, T., et al. (2021). Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nat Genet* 53, 65-75. [10.1038/s41588-020-00748-0](https://doi.org/10.1038/s41588-020-00748-0).
4. Plym, A., Penney, K.L., Kalia, S., Kraft, P., Conti, D.V., Haiman, C., Mucci, L.A., and Kibel, A.S. (2021). Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer. *J Natl Cancer Inst*. [10.1093/jnci/djab058](https://doi.org/10.1093/jnci/djab058).

5. International Schizophrenia Consortium, Purcell, S.M., Wray, N.R., Stone, J.L., Visscher, P.M., O'Donovan, M.C., Sullivan, P.F., and Sklar, P. (2009). Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature* 460, 748-752. [10.1038/nature08185](https://doi.org/10.1038/nature08185).
6. Khera, A.V., Chaffin, M., Aragam, K.G., Haas, M.E., Roselli, C., Choi, S.H., Natarajan, P., Lander, E.S., Lubitz, S.A., Ellinor, P.T., and Kathiresan, S. (2018). Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet* 50, 1219-1224. [10.1038/s41588-018-0183-z](https://doi.org/10.1038/s41588-018-0183-z).
7. Thomas, M., Sakoda, L.C., Hoffmeister, M., Rosenthal, E.A., Lee, J.K., van Duijnhoven, F.J.B., Platz, E.A., Wu, A.H., Dampier, C.H., de la Chapelle, A., et al. (2020). Genome-wide Modeling of Polygenic Risk Score in Colorectal Cancer Risk. *Am J Hum Genet* 107, 432-444. [10.1016/j.ajhg.2020.07.006](https://doi.org/10.1016/j.ajhg.2020.07.006).
8. Dikilitas, O., Schaid, D.J., Kosel, M.L., Carroll, R.J., Chute, C.G., Denny, J.A., Fedotov, A., Feng, Q., Hakonarson, H., Jarvik, G.P., et al. (2020). Predictive Utility of Polygenic Risk Scores for Coronary Heart Disease in Three Major Racial and Ethnic Groups. *Am J Hum Genet* 106, 707-716. [10.1016/j.ajhg.2020.04.002](https://doi.org/10.1016/j.ajhg.2020.04.002).
9. Zhang, Y.D., Hurson, A.N., Zhang, H., Choudhury, P.P., Easton, D.F., Milne, R.L., Simard, J., Hall, P., Michailidou, K., Dennis, J., et al. (2020). Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nat Commun* 11, 3353. [10.1038/s41467-020-16483-3](https://doi.org/10.1038/s41467-020-16483-3).

10. Prive, F., Arbel, J., and Vilhjalmsson, B.J. (2020). LDpred2: better, faster, stronger. *Bioinformatics*. 10.1093/bioinformatics/btaa1029.
11. Ruan, Y., Feng, Y.A., Chen, C., Lam, M., Initiatives, S.G.A., Sawa, A., Martin, A.R., Qin, S., Huang, H., and Ge, T. (preprint). Improving Polygenic Prediction in Ancestrally Diverse Populations. medRxiv.
12. Song, S., Jiang, W., Hou, L., and Zhao, H. (2020). Leveraging effect size distributions to improve polygenic risk scores derived from summary statistics of genome-wide association studies. *PLoS Comput Biol* 16, e1007565. 10.1371/journal.pcbi.1007565.
13. International HapMap Consortium, Altshuler, D.M., Gibbs, R.A., Peltonen, L., Altshuler, D.M., Gibbs, R.A., Peltonen, L., Dermitzakis, E., Schaffner, S.F., Yu, F., et al. (2010). Integrating common and rare genetic variation in diverse human populations. *Nature* 467, 52-58. 10.1038/nature09298.
14. Gaziano, J.M., Concato, J., Brophy, M., Fiore, L., Pyarajan, S., Breeling, J., Whitbourne, S., Deen, J., Shannon, C., Humphries, D., et al. (2016). Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* 70, 214-223. 10.1016/j.jclinepi.2015.09.016.
15. Mucci, L.A., Hjelmborg, J.B., Harris, J.R., Czene, K., Havelick, D.J., Scheike, T., Graff, R.E., Holst, K., Moller, S., Unger, R.H., et al. (2016). Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. *JAMA* 315, 68-76. 10.1001/jama.2015.17703.
16. Sampson, J.N., Wheeler, W.A., Yeager, M., Panagiotou, O., Wang, Z., Berndt, S.I., Lan, Q., Abnet, C.C., Amundadottir, L.T., Figueroa, J.D., et al. (2015).

Analysis of Heritability and Shared Heritability Based on Genome-Wide

Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst* 107, djv279.

10.1093/jnci/djv279.

17. Prive, F., Aschard, H., Carmi, S., Folkersen, L., Hoggart, C., O'Reilly, P.F., and Vilhjalmsson, B.J. (2022). Portability of 245 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same cohort. *Am J Hum Genet* 109, 12-23. 10.1016/j.ajhg.2021.11.008.
18. Yu, H., Shi, Z., Lin, X., Bao, Q., Jia, H., Wei, J., Helfand, B.T., Zheng, S.L., Duggan, D., Lu, D., et al. (2020). Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment. *Prostate* 80, 83-87. 10.1002/pros.23920.

Figures







Figure 1. Comparison of PRS performance in the CA UG Study and the UK Biobank testing data. PRS performance is evaluated using area under the curve (AUC) estimated in men of A) African and C) European ancestry and OR of prostate cancer for each SD increase in PRS in men of B) African and D) European ancestry.







Figure 2. Comparison of PRS performance in the MVP validation data. PRS performance is evaluated using area under the curve (AUC) estimated in men of A) African and C) European ancestry and OR of prostate cancer for each SD increase in PRS in men of B) African and D) European ancestry.